Base excision repair and targeted therapy strategies

doi:10.3760/cma.j.issn.1673-422X.2017.11.013

Abstract

Abstract: Base excision repair (BER) is an important pathway for DNA oxidative damage repair, and mutations in this pathway cause gene instability and increase cancer risk. A large number of studies have shown that abnormal expression of key proteins in the BER pathway in a variety of tumors, such as DNA glycosylase, apurinic/apyrimidinic endonuclease 1, DNA polymerase and so on. Single nucleotide polymorphisms of these proteins affect the repair activity of tumor cells, and are expected to be important indicators for the diagnosis, treatment and evaluation of prognosis.

Key words: DNA repair, Polymorphism, Genomic instability, Base excision repair

张天棋，王红兵. Base excision repair and targeted therapy strategies[J]. Journal of International Oncology, 2017, 44(11): 856-859.

References

［1］ Dutta A, Yang C, Sengupta S, et al. New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins［J］. Cell Mol Life Sci, 2015, 72(9): 1679-1698. DOI: 10.1007/s00018-014-1820-z. ［2］ Abbotts R, Wilson DM 3rd. Coordination of DNA single strand break repair［J］. Free Radic Biol Med, 2017, 107: 228-244. DOI: 10.1016/j.freeradbiomed.2016.11.039. ［3］ Bharti SK, Brosh RM. Finetuning DNA repair by protein acetylation［J］. Cell Cycle, 2016, 15(15): 1952-1953. DOI: 10.1080/15384101.2016.1191250. ［4］ Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety［J］. Ann Oncol, 2016, 27(6): 1013-1019. DOI: 10.1093/annonc/mdw133. ［5］ Gavande NS, VandervereCarozza PS, Hinshaw HD, et al. DNA repair targeted therapy: the past or future of cancer treatment?［J］. Pharmacol Ther, 2016, 160: 65-83. DOI: 10.1016/j.pharmthera.2016.02.003. ［6］ Mateo J, Carreira S, Sandhu S, et al. DNArepair defects and olaparib in metastatic prostate cancer［J］. N Engl J Med, 2015, 373(18): 1697-1708. DOI: 10.1056/NEJMoa1506859. ［7］ Mccrudden CM, O′rourke MG, Cherry KE, et al. Vasoactivity of rucaparib, a PARP1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself［J］. PLoS One, 2015, 10(2): e0118187. DOI: 10.1371/journal.pone.0118187. ［8］ Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADPribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer［J］. Br J Cancer, 2016, 114(7): 723730. DOI: 10.1038/bjc.2016.41. ［9］ Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinumsensitive, recurrent ovarian cancer［J］. N Engl J Med, 2016, 375(22): 2154-2164. DOI: 10.1056/NEJMoa1611310. ［10］ Engert F, Kovac M, Baumhoer D, et al. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics［J］. Oncotarget, 2017, 8(30): 48794-48806. DOI: 10.18632/oncotarget.10720. ［11］ Kim Y, Kim A, Sharip A, et al. Reverse the resistance to PARP inhibitors［J］. Int J Biol Sci, 2017, 13(2): 198-208. DOI: 10.7150/ijbs.17240. ［12］ Laev SS, Salakhutdinov NF, Lavrik OI. Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref1)［J］. Bioorg Med Chem, 2017, 25(9): 2531-2544. DOI: 10.1016/j.bmc.2017.01.028. ［13］ Tell G, Fantini D, Quadrifoglio F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment［J］. Cell Mol Life Sci, 2010, 67(21): 3589-3608. DOI: 10.1007/s00018-010-0486-4. ［14］崔熠, 金孝华, 胡玮. 大豆异黄酮对乳腺癌细胞抑癌基因启动子区的去甲基化作用研究［J］. 中国计划生育学杂志, 2014, 22(6): 381-385. DOI: 10.3969/j.issn.1004-8189.2014.06. ［15］王东. 基于DNA损伤修复的分子靶向治疗: 肿瘤靶向治疗的新篇章［J］. 第三军医大学学报, 2014, 36(22): 22432248. ［16］ He LF, Luo L, Zhu H, et al.FEN1 promotes tumor progression and confers cisplatin resistance in NSCLC［J］. Mol Oncol, 2017, 11(6): 640-654. DOI: 10.1002/1878-0261.12058. ［17］ Zhou T, Pan F, Cao Y, et al. R152C DNA pol β mutation impairs base excision repair and induces cellular transformation［J］. Oncotarget, 2016, 7(6): 6902-6915. DOI: 10.18632/oncotarget.6849. ［18］ Nemec AA, Donigan KA, Murphy DL, et al. Colon cancerassociated DNA polymerase β variant induces genomic instability and cellular transformation［J］. J Biol Chem, 2012, 287(28): 23840-23849. DOI: 10.1074/jbc.M112.362111. ［19］ Jaiswal AS, Banerjee S, Aneja R, et al. DNA polymerase-β as a novel target for chemotherapeutic intervention of colorectal cancer［J］. PLoS One, 2011, 6(2): e16691. DOI: 10.1371/journal.pone.0016691. ［20］ Capp JP, Boudsocq F, Bergoglio V, et al. The R438W polymorphism of human DNA polymerase lambda triggers cellular sensitivity to camptothecin by compromising the homologous recombination repair pathway［J］. Carcinogenesis, 2010, 31(10): 17421747. DOI: 10.1093/carcin/bgq166. ［21］ Mentegari E, Kissova M, Bavagnoli L, et al. DNA polymerases λ and β: the doubleedged swords of DNA repair［J］. Genes (Basel), 2016, 7(9): 57. DOI: 10.3390/genes7090057. ［22］ Gao XR, Zhang SL, Yang YF, et al. FEN1 69G>A and 4150G>T polymorphisms and cancer risk in Chinese population［J］. Sci Rep, 2014, 4: 6183. DOI: 10.1038/srep06183. ［23］ He L, Zhang Y, Sun H, et al. Targeting DNA flap endonuclease 1 to impede breast cancer progression［J］. EBioMedicine, 2016, 14: 3243. DOI: 10.1016/j.ebiom.2016.11.012. ［24］ TalsethPalme BA.The genetic basis of colonic adenomatous polyposis syndromes［J］. Hered Cancer Clin Pract, 2017, 15: 5. DOI: 10.1186/s130530170065x. ［25］马俊, 侯小强, 郑秋生, 等. DNA修复酶基因NEIL1的AI RNA编辑水平在白血病和乳腺癌细胞中的下调［J］. 军事医学, 2014, 38(6): 458462. DOI: 10.7644/j.issn.1674-9960.2014.06.013. ［26］ Dizdaroglu M, Coskun E, Jaruga P. Repair of oxidatively induced DNA damage by DNA glycosylases: mechanisms of action, substrate specificities and excision kinetics［J］. Mutat Res, 2017, 771: 99-127. DOI: 10.1016/j.mrrev.2017.02.001. ［27］付婷, 秦立强, 潘旭东, 等. XRCC1基因多态性与晚期非小细胞肺癌铂类化疗敏感性关系的Meta分析［J］. 江苏医药, 2015, 41(12): 14011403. ［28］ Sanjari Moghaddam A, Nazarzadeh M, Noroozi R, et al. XRCC1 and OGG1 gene polymorphisms and breast cancer: a systematic review of literature［J］. Iran J Cancer Prev, 2016, 9(1): e3467. DOI: 10.17795/ijcp-3467.

[1]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[2]	Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer [J]. Journal of International Oncology, 2022, 49(10): 635-638.
[3]	Shen Xiabo, Li Yan, Wang Wei. Roles of AGGF1 in tumor and its regulatory mechanisms [J]. Journal of International Oncology, 2019, 46(3): 166-169.
[4]	Zhang Huibo, Yang yanying, Song Qibin. Association between MTHFR polymorphisms and colorectal cancer [J]. Journal of International Oncology, 2017, 44(8): 619-621.
[5]	Chen Zhipeng, Lu Weidong, Zuo Yun, Zhu Lingjun, Song Yu, Zhou Fang, Zhang Yongqin. Relationship between APC gene 3′-untranslated region rs1804197 polymorphism and colorectal cancer susceptibility [J]. Journal of International Oncology, 2017, 44(6): 433-.
[6]	Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC Lys939Gln(A/C) gene polymorphism and the susceptibility of gastric cancer: a Metaanalysis [J]. Journal of International Oncology, 2016, 43(8): 597-602.
[7]	LI Tao, LAI Chun-Feng, QIU Bo, ZOU Hao-Yuan, YANG Yu-Hui. Relationship between CYP2E1 genetic polymorphism and susceptibility of gastric cancer in Hakkaness [J]. Journal of International Oncology, 2016, 43(7): 495-498.
[8]	Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC rs2228000(C/T) polymorphism and the susceptibility of breast cancer: a Metaanalysis [J]. Journal of International Oncology, 2016, 43(10): 752-757.
[9]	LIU Jia, ZHU Qin-Mei, HU Hong-Yi, WANG Su. Association between polymorphism of interleukin28B rs12979860 T/C and susceptibility of hepatocellular carcinoma: a Metaanalysis [J]. Journal of International Oncology, 2015, 42(5): 342-346.
[10]	Zeng Hui, Zeng Tuo, Long Xinghua. Roles of polymorphism in promoter region of miR-34b/c in cancer: a Meta analysis [J]. Journal of International Oncology, 2015, 42(1): 27-31.
[11]	Tian Yuan, Shan Zezhi, Peng Jiayuan, Wang Yu. ERCC1 gene polymorphism in gastric cancer [J]. Journal of International Oncology, 2014, 41(8): 666-668.
[12]	Fu Ping, Wang Fuxia, Cui Lixian, Cui Bin, Liu Jie. Polymorphism of SMAD7 and susceptibility to nonsmall cell lung cancer [J]. Journal of International Oncology, 2014, 41(5): 383-386.
[13]	DENG Cheng-Hui, GUAN Quan-Lin, JIANG Lei, LI Xiao-Qi, GAN Liang-Liang, WEI Kong-Kong. Association between Ile105Val polymorphism of GSTP1 and sensitivity to platinumbased chemotherapy in advanced gastric cancer: a Metaanalysis [J]. Journal of International Oncology, 2014, 41(4): 309-314.
[14]	ZHAO Na, YANG Xi-Gui, CAO Dian-Feng, GAO Ping, ZHANG Bao-Ling. Expression of HLADQA1 gene polymorphism in the lung cancer patients with pneumoconiosis [J]. Journal of International Oncology, 2014, 41(10): 779-781.
[15]	SUN Hao-Yao, ZHOU Jun-Dong, MENG Xing-Jun, LI Xiao-Qing, YU Jian, WU Jin-Chang. DNA polymerase iota and cancer [J]. Journal of International Oncology, 2014, 41(10): 731-733.